REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

06 Nov 2023 13:05:18 By Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

01 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

31 Oct 2023 13:15:00 By Nasdaq GlobeNewswire

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

21 Oct 2023 23:30:28 By Nasdaq GlobeNewswire

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

13 Oct 2023 08:50:29 By Nasdaq GlobeNewswire

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

04 Oct 2023 13:05:07 By Nasdaq GlobeNewswire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

19 Sep 2023 04:00:38 By Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

17 Aug 2023 13:05:58 By Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

08 Aug 2023 13:05:04 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

03 Aug 2023 13:05:54 By Nasdaq GlobeNewswire

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

01 Aug 2023 04:00:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

08 Jun 2023 13:05:17 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

24 May 2023 13:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

08 May 2023 13:02:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

01 May 2023 13:05:37 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

13 Apr 2023 13:05:40 By Nasdaq GlobeNewswire

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

06 Apr 2023 04:00:54 By Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

07 Mar 2023 13:02:17 By Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

02 Mar 2023 18:15:55 By Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

01 Mar 2023 13:17:35 By Nasdaq GlobeNewswire